Urology billing: cystoscopy bundling, urodynamics components and PSA coverage

Nearly every therapeutic cystoscopic procedure begins with looking. The surgeon introduces the scope, inspects the bladder, and then does something — removes a stone, resects a tumour, places a stent, injects an agent. The looking is how the doing became possible, and the therapeutic codes are valued accordingly.

Billing diagnostic cystoscopy alongside a therapeutic cystoscopic procedure in the same session therefore triggers an NCCI edit. The service was performed; it was also already paid for.

The legitimate exception is narrow and needs the note to establish it: a diagnostic cystoscopy performed at a separate session, or an examination of a genuinely separate site. Neither is created by appending a modifier to a same-session claim.

What makes this expensive rather than merely annoying is volume. Urology performs a very large number of cystoscopic procedures, so a charge template that adds diagnostic cystoscopy by default produces a recurring, systematic edit across the practice's highest-frequency service.

A urodynamic study is not one service. It is a set of measurements that may be performed together, and each has its own code. The practice bills the components actually performed, and each requires its own documentation of the equipment used and the physician's interpretation.

Practices commonly configure a urodynamics charge set that fires as a block whenever a study is performed. It is efficient, and it bills components that were not always performed.

Payer scrutiny of urodynamics is high precisely because this pattern is common and detectable — a practice reporting an identical component set on every study is visible in claims data without anyone reading a chart. The finding, when it comes, covers the whole period rather than a sampled claim.

The requirement is not onerous. The study report should state which measurements were obtained, on what equipment, and carry the interpreting physician's findings for each. A study that genuinely included all components is billable for all of them; the report simply has to show it.

There is a professional and technical split here as well. Where the practice owns the equipment and interprets, it bills globally. Where the study is performed elsewhere, or interpreted by someone outside the practice, the components split — and the same place-of-service logic that governs radiology applies.

Prostate-specific antigen testing is covered by Medicare as a screening service on a defined annual frequency for men over a qualifying age, and separately as a diagnostic test when ordered to evaluate a known condition or a specific clinical concern. The two are not interchangeable and use different codes.

Billing the diagnostic code for what was a screening test produces a claim that may pay but was not accurate. Billing the screening code where the patient had symptoms or a known diagnosis understates the service. And billing screening more frequently than the covered interval denies, correctly, on frequency.

The determinant is the ordering physician's indication, which means the same discipline that governs radiology applies: the reason for the test is established before it is performed, not reconstructed at billing.

Digital rectal examination as a screening service has its own coverage and its own frequency. Where both are performed at a screening visit, both are reportable under the screening benefit rather than folded into an office visit.

Urology performs a high volume of small procedures in the office, and their billing failures are unglamorous: missing laterality, unreported supplies, and evaluation and management services billed alongside procedures without a separately identifiable service to support them.

The newer office and outpatient treatments for benign prostatic hyperplasia are among the most tightly managed procedures in the specialty. Payers publish medical policies stating what has to be true before they will authorise, and those policies are specific.

Common requirements include a documented prostate volume within a stated range, a symptom score above a threshold, and documented failure or intolerance of medical therapy over a defined period. Each is knowable before the case is scheduled and each is a denial if absent.

The pattern that costs practices is performing the procedure on sound clinical judgement without confirming the policy criteria were documented in the terms the policy uses. A symptom score recorded as a number satisfies the requirement; a note describing bothersome symptoms does not, however accurate it is.

Because these procedures carry meaningful claim values, and because authorisation is nearly always required, this is the category where a single missed prerequisite costs the most in absolute terms.

Urology's three dominant denial categories share a structure: each is decided by information that exists before adjudication and is either recorded or not. Whether the cystoscopy was diagnostic or the entry to a therapeutic procedure is in the operative note. Which urodynamic components were performed is in the study report. Why the PSA was ordered is in the order.

Optum's analysis of 124 million claim remits found 84% of denials potentially avoidable, with 22% of those unrecoverable once they occur. The bundling category in particular is close to fully unrecoverable — a correctly applied NCCI edit is not overturned by explaining that the work was performed.

Premier Inc. puts the average administrative cost of fighting a denied claim at $57.23, with roughly 70% eventually overturned. For the authorisation denials on high-value BPH procedures, appealing is clearly worth it. For the systematic bundling edits, there is nothing to appeal — only a charge template to correct, which costs nothing and stops the whole category at once.